                         SEQUENCE LISTING

<110>  Asclepix Therapeutics, LLC
       The Johns Hopkins University
 
<120>  METHODS FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS FOR 
       ACTIVATING TIE2 RECEPTOR

<130>  ASX-011PC/114293-5011

<150>  US 62/540,880
<151>  2017-08-03

<160>  37    

<170>  PatentIn version 3.5

<210>  1
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is M, A, or G

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  X is F, A, Y, or G

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  X is M, A, G, dA, or Nle

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  X is F, A, Y, G, or 4-ClPhe

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  X is Abu, G, S, A, V, T, I, L or Allyl-Gly

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  X is Abu, G, S, A, V, T, I, L or Allyl-Gly

<400>  1

Leu Arg Arg Phe Ser Thr Xaa Pro Xaa Xaa Xaa Xaa Asn Ile Asn Asn 
1               5                   10                  15      


Val Xaa Asn Phe 
            20  


<210>  2
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  2

Leu Arg Arg Phe Ser Thr Ala Pro Phe Ala Phe Ile Asp Ile Asn Asp 
1               5                   10                  15      


Val Ile Asn Phe 
            20  


<210>  3
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  3

Leu Arg Arg Phe Ser Thr Ala Pro Phe Ala Phe Ile Asn Ile Asn Asn 
1               5                   10                  15      


Val Ile Asn Phe 
            20  


<210>  4
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  4

Leu Arg Arg Phe Ser Thr Ala Pro Phe Ala Phe Ile Asp Ile Asn Asp 
1               5                   10                  15      


Val Ile Asn Trp 
            20  


<210>  5
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  5

Phe Thr Asn Ile Asn Asn Val Thr Asn 
1               5                   


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  6

Phe Thr Asp Ile Asn Asp Val Thr Asn 
1               5                   


<210>  7
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  X is Abu

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  X is Abu

<400>  7

Leu Arg Arg Phe Ser Thr Met Pro Phe Met Phe Xaa Asn Ile Asn Asn 
1               5                   10                  15      


Val Xaa Asn Phe 
            20  


<210>  8
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  X is Abu

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  X is Abu

<400>  8

Leu Arg Arg Phe Ser Thr Met Pro Ala Met Phe Xaa Asn Ile Asn Asn 
1               5                   10                  15      


Val Xaa Asn Phe 
            20  


<210>  9
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  X is Abu

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  X is Abu

<400>  9

Leu Arg Arg Phe Ser Thr Met Pro Phe Ala Phe Xaa Asn Ile Asn Asn 
1               5                   10                  15      


Val Xaa Asn Phe 
            20  


<210>  10
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  X is Abu

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  X is Abu

<400>  10

Leu Arg Arg Phe Ser Thr Met Pro Phe Met Ala Xaa Asn Ile Asn Asn 
1               5                   10                  15      


Val Xaa Asn Phe 
            20  


<210>  11
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  X is Nle

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  X is Abu

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  X is Abu

<400>  11

Leu Arg Arg Phe Ser Thr Met Pro Phe Xaa Phe Xaa Asn Ile Asn Asn 
1               5                   10                  15      


Val Xaa Asn Phe 
            20  


<210>  12
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  X is 4-ClPhe

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  X is Abu

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  X is Abu

<400>  12

Leu Arg Arg Phe Ser Thr Met Pro Phe Met Xaa Xaa Asn Ile Asn Asn 
1               5                   10                  15      


Val Xaa Asn Phe 
            20  


<210>  13
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  13

Leu Arg Arg Phe Ser Thr Met Pro Phe Met Phe Ser Asn Ile Asn Asn 
1               5                   10                  15      


Val Ser Asn Phe 
            20  


<210>  14
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  14

Leu Arg Arg Phe Ser Thr Met Pro Phe Met Phe Ala Asn Ile Asn Asn 
1               5                   10                  15      


Val Ala Asn Phe 
            20  


<210>  15
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  15

Leu Arg Arg Phe Ser Thr Met Pro Phe Met Phe Ile Asn Ile Asn Asn 
1               5                   10                  15      


Val Ile Asn Phe 
            20  


<210>  16
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  16

Leu Arg Arg Phe Ser Thr Met Pro Phe Met Phe Thr Asn Ile Asn Asn 
1               5                   10                  15      


Val Thr Asn Phe 
            20  


<210>  17
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  X is AllyGly

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  X is AllyGly

<400>  17

Leu Arg Arg Phe Ser Thr Met Pro Phe Met Phe Xaa Asn Ile Asn Asn 
1               5                   10                  15      


Val Xaa Asn Phe 
            20  


<210>  18
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  18

Leu Arg Arg Phe Ser Thr Met Pro Phe Met Phe Val Asn Ile Asn Asn 
1               5                   10                  15      


Val Val Asn Phe 
            20  


<210>  19
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  X is dA

<400>  19

Leu Arg Arg Phe Ser Thr Met Pro Phe Xaa Phe Ile Asn Ile Asn Asn 
1               5                   10                  15      


Val Ile Asn Phe 
            20  


<210>  20
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  20

Leu Arg Arg Phe Ser Thr Met Pro Phe Ala Phe Ile Asn Ile Asn Asn 
1               5                   10                  15      


Val Ile Asn Phe 
            20  


<210>  21
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  21

Leu Arg Arg Phe Ser Thr Ala Pro Phe Ala Phe Ile Asn Ile Asn Asn 
1               5                   10                  15      


Val Ile Asn Phe 
            20  


<210>  22
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  X is dA

<400>  22

Leu Arg Arg Phe Ser Thr Ala Pro Phe Xaa Phe Ile Asp Ile Asn Asp 
1               5                   10                  15      


Val Ile Asn Phe 
            20  


<210>  23
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X is Abu

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X is Abu

<400>  23

Phe Xaa Asn Ile Asn Asn Val Xaa Asn 
1               5                   


<210>  24
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  24

Phe Thr Asn Ile Asn Asn Val Thr Asn 
1               5                   


<210>  25
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  25

Phe Ile Asn Ile Asn Asn Val Ile Asn Phe 
1               5                   10  


<210>  26
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  26

Phe Ser Asn Ile Asn Asn Val Ser Asn Phe 
1               5                   10  


<210>  27
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  27

Phe Ala Asn Ile Asn Asn Val Ala Asn Phe 
1               5                   10  


<210>  28
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X is AllyGly

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X is AllyGly

<400>  28

Phe Xaa Asn Ile Asn Asn Val Xaa Asn Phe 
1               5                   10  


<210>  29
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  29

Phe Val Asn Ile Asn Asn Val Val Asn Phe 
1               5                   10  


<210>  30
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X is Abu

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X is Abu

<400>  30

Ala Xaa Asn Ile Asn Asn Val Xaa Asn Phe 
1               5                   10  


<210>  31
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X is 4-ClPhe

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X is Abu

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X is Abu

<400>  31

Xaa Xaa Asn Ile Asn Asn Val Xaa Asn Phe 
1               5                   10  


<210>  32
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X is dL

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X is dL

<400>  32

Xaa Arg Arg Xaa Arg Arg Phe Ser Thr Ala Pro Phe Ala Phe Ile Asp 
1               5                   10                  15      


Ile Asn Asp Val Ile Asn Phe 
            20              


<210>  33
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X is dL

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  X is dF

<400>  33

Xaa Arg Arg Phe Ser Thr Ala Pro Phe Ala Phe Ile Asp Ile Asn Asp 
1               5                   10                  15      


Val Ile Asn Xaa 
            20  


<210>  34
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  34

Phe Ile Asp Ile Asn Asp Val Ile Asn Phe 
1               5                   10  


<210>  35
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  35

Phe Ile Asp Ile Asn Asp Val Ile Asn Trp 
1               5                   10  


<210>  36
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide

<400>  36

Phe Thr Asp Ile Asn Asp Val Thr Asn 
1               5                   


<210>  37
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Peptide


<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  X is dF

<400>  37

Leu Arg Arg Phe Ser Thr Ala Pro Phe Ala Phe Ile Asp Ile Asn Asp 
1               5                   10                  15      


Val Ile Asn Xaa 
            20  


